Soluble biglycan: A potential mediator of cartilage degradation in osteoarthritis

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Barreto, Goncalo ^a   Soininen, Antti ^b   Ylinen, Pekka ^b   Sandelin, Jerker ^b   Konttinen, Yrjö T ^a,b   Nordström, Dan C ^a   Eklund, Kari K ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORTON ORTHOPAEDIC HOSPITAL   (Finland)

Author keywords

Biglycan; Cartilage; Chondrocytes; Decorin; Innate immune response; Osteoarthritis; Toll like receptors

Indexed keywords

AGGRECAN; AGGRECANASE 1; AGGRECANASE 2; BIGLYCAN; CATHEPSIN K; COLLAGEN TYPE 2; COLLAGENASE 3; DECORIN; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MESSENGER RNA; NITRIC OXIDE; PROTEOGLYCAN; TATA BINDING PROTEIN; TOLL LIKE RECEPTOR 4; BGN PROTEIN, HUMAN; BIOLOGICAL MARKER;

ACAN GENE; ADAMTS4 GENE; ADAMTS5 GENE; ADULT; AGED; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE EXPLANT; COL2A1 GENE; CONTROLLED STUDY; CTSK GENE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAPDH GENE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KNEE MENISCUS RUPTURE; KNEE OSTEOARTHRITIS; MALE; MMP13 GENE; MMP9 GENE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REPORTER GENE; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TBP GENE; ARTICULAR CARTILAGE; CHEMISTRY; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; ARTHRITIS, RHEUMATOID; BIGLYCAN; BIOMARKERS; CARTILAGE, ARTICULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; REAL-TIME POLYMERASE CHAIN REACTION; SYNOVIAL FLUID;

EID: 84951859446     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0902-0     Document Type: Article

References (52)

1. Woolf AD. The bone and joint decade: strategies to reduce the burden of disease: the Bone and Joint Monitor Project. J Rheumatol Suppl. 2003;67:6-9.
2. Felson DT. Osteoarthritis: priorities for osteoarthritis research: much to be done. Nat Rev Rheumatol. 2014;10:447-8.
3. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21:16-21.
4. Gao Y, Liu S, Huang J, Guo W, Chen J, Zhang L, et al. The ECM-cell interaction of cartilage extracellular matrix on chondrocytes. Biomed Res Int. 2014;2014:648459.
5. Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta. 2012;1824:133-45.
6. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum. 2006;54:2152-63.
7. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002;168:5233-9.
8. Chang MY, Tanino Y, Vidova V, Kinsella MG, Chan CK, Johnson PY, et al. A rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease. Matrix Biol. 2014;34:1-12.
9. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276:10229-33.
10. Campo GM, Avenoso A, Campo S, D'Ascola A, Nastasi G, Calatroni A. Molecular size hyaluronan differently modulates Toll-like receptor-4 in LPS-induced inflammation in mouse chondrocytes. Biochimie. 2010;92:204-15.
11. Schelbergen RFP, Blom AB, van den Bosch MHJ, Slöetjes A, Abdollahi-Roodsaz S, Schreurs BW, et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum. 2012;64:1477-87.
12. Gay NJ, Gangloff M, Weber AN. Toll-like receptors as molecular switches. Nat Rev Immunol. 2006;6:693-8.
13. Roughley PJ. The structure and function of cartilage proteoglycans. Eur Cell Mater. 2006;12:92-101.
14. Anders HJ, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, Toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol. 2014;25:1387-400.
15. Song R, Zeng Q, Ao L, Yu JA, Cleveland JC, Zhao KS, et al. Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2. Arterioscler Thromb Vasc Biol. 2012;32:2711-20.
16. Moreth K, Frey H, Hubo M, Zeng-Brouwers J, Nastase MV, Hsieh LT, et al. Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix Biol. 2014;35:143-51.
17. Moreth K, Brodbeck R, Babelova A, Gretz N, Spieker T, Zeng-Brouwers J, et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest. 2010:120;4251-72.
18. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal. 2011;4:ra75.
19. Blom AB, van den Berg WB. The synovium and its role in osteoarthritis. In: Bronner F, Farach-Carson MC, editors. Bone and osteoarthritis. London: Springer; 2007. p. 65-79.
20. Ni GX, Li Z, Zhou YZ. The role of small leucine-rich proteoglycans in osteoarthritis pathogenesis. Osteoarthritis Cartilage. 2014;22:896-903.
21. Polgar A, Falus A, Koo E, Ujfalussy I, Sesztak M, Szuts I, et al. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology (Oxford). 2003;42:522-7.
22. Bock HC, Michaeli P, Bode C, Schultz W, Kresse H, Herken R, et al. The small proteoglycans decorin and biglycan in human articular cartilage of late-stage osteoarthritis. Osteoarthritis Cartilage. 2001;9:654-63.
23. Monfort J, Tardif G, Reboul P, Mineau F, Roughley P, Pelletier JP, et al. Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site. Arthritis Res Ther. 2006;8:R26.
24. Melching LI, Fisher WD, Lee ER, Mort JS, Roughley PJ. The cleavage of biglycan by aggrecanases. Osteoarthritis Cartilage. 2006;14:1147-54.
25. Melrose J, Fuller ES, Roughley PJ, Smith MM, Kerr B, Hughes CE, et al. Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissues. Arthritis Res Ther. 2008;10:R79.
26. Dougados M, Ayral X, Listrat V, Gueguen A, Bahuaud J, Beaufils P, et al. The SFA system for assessing articular cartilage lesions at arthroscopy of the knee. Arthroscopy. 1994;10:69-77.
27. Heinola T, Kouri VP, Clarijs P, Ciferska H, Sukura A, Salo J, et al. High mobility group box-1 (HMGB-1) in osteoarthritic cartilage. Clin Exp Rheumatol. 2010;28:511-8.
28. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51 Suppl 6:vi5-9.
29. Vlachakis D, Tsaniras SC, Feidakis C, Kossida S. Molecular modelling study of the 3D structure of the biglycan core protein, using homology modelling techniques. J Mol Biochem. 2013;2:85-93.
30. Bobacz K, Sunk IG, Hofstaetter JG, Amoyo L, Toma CD, Akira S, et al. Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of Toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum. 2007;56:1880-93.
31. Nastase MV, Iozzo RV, Schaefer L. Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology. Biochim Biophys Acta. 2014;1840:2460-70.
32. Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013;280:2165-79.
33. Young AA, Smith MM, Smith SM, Cake MA, Ghosh P, Read RA, et al. Regional assessment of articular cartilage gene expression and small proteoglycan metabolism in an animal model of osteoarthritis. Arthritis Res Ther. 2005;7:R852-61.
34. Monach PA, Hueber W, Kessler B, Tomooka BH, BenBarak M, Simmons BP, et al. A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2009;106:15867-72.
35. Zvaifler NJ. Rheumatoid synovitis: an extravascular immune complex disease. Arthritis Rheum. 1974;17:297-305.
36. Nandakumar KS, Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther. 2006;8:223.
37. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, et al. Identification of a central role for complement in osteoarthritis. Nat Med. 2011;17:1674-9.
38. Barreto G, Sillat T, Soininen A, Ylinen P, Salem A, Konttinen YT, et al. Do changing Toll-like receptor profiles in different layers and grades of osteoarthritis cartilage reflect disease severity? J Rheumatol. 2013;40:695-702.
39. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
40. Feng X, Guo Z, Nourbakhsh M, Hauser H, Ganster R, Shao L, et al. Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: The role of NF-κB-repressing factor (NRF) in basal repression of the hiNOS gene. Proc Natl Acad Sci U S A. 2002;99:14212-7.
41. Boileau C, Martel-Pelletier J, Moldovan F, Jouzeau JY, Netter P, Manning PT, et al. The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide. Arthritis Rheum. 2002;46:2637-47.
42. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44:1237-47.
43. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors. J Biol Chem. 2009;284:24035-48.
44. Miosge N, Flachsbart K, Goetz W, Schultz W, Kresse H, Herken R. Light and electron microscopical immunohistochemical localization of the small proteoglycan core proteins decorin and biglycan in human knee joint cartilage. Histochem J. 1994;26:939-45.
45. Knight MM, McGlashan SR, Garcia M, Jensen CG, Poole CA. Articular chondrocytes express connexin 43 hemichannels and P2 receptors - a putative mechanoreceptor complex involving the primary cilium? J Anat. 2009;214:275-83.
46. Blom AB, van Lent PL, Holthuysen AE, van der Kraan PM, Roth J, van Rooijen N, et al. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage. 2004;12:627-35.
47. Blom AB, van Lent PL, Libregts S, Holthuysen AE, van der Kraan PM, van Rooijen N, et al. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum. 2007;56:147-57.
48. Mueller MB, Tuan RS. Anabolic/catabolic balance in pathogenesis of osteoarthritis: identifying molecular targets. PM R. 2011;3(6 Suppl 1):S3-11.
49. Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, et al. Hypoxia-inducible factor-2aα is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med. 2010;16:687-93.
50. Malfait AM, Arner EC, Song RH, Alston JT, Markosyan S, Staten N, et al. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch Biochem Biophys. 2008;478:43-51.
51. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A. 1990;87:364-8.
52. Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003;278:45539-45.